An open-label long-term phase III extension trial to evaluate the safety and efficacy of pregabalin in Japanese patients with fibromyalgia

Modern Rheumatology

Volumn 23, Issue 6, 2013, Pages 1108-1115

  Ohta, Hiroyoshi ^a   Oka, Hiroshi ^b   Usui, Chie ^c   Ohkura, Masayuki ^a   Suzuki, Makoto ^a   Nishioka, Kusuki ^d  

^a PFIZER INC   (United States)

^b TOKYO MEDICAL UNIVERSITY HACHIOJI MEDICAL CENTER   (Japan)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Clinical trial; Fibromyalgia; Japan; Pain; Safety

Indexed keywords

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBROMYALGIA; GAMMA-AMINOBUTYRIC ACID; HUMANS; JAPAN; MALE; MIDDLE AGED; PAIN MEASUREMENT; TREATMENT OUTCOME;

EID: 84894363581     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-012-0803-x     Document Type: Article

References (26)

1. Ablin JN, Cohen H, Buskila D. Mechanisms of disease: genetics of fibromyalgia. Nat Clin Pract Rheumatol. 2006;2(12): 671-8.
2. Bradley LA. Pathophysiology of fibromyalgia. Am J Med. 2009;122(12 suppl):S22-30.
3. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthr Rheum. 1990;33(2): 160-72.
4. Wolfe F, Clauw DJ, Fitzcharles M-A, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthr Care Res (Hoboken). 2010;62(5): 600-10.
5. Usui C, Hatta K, Aratani S, Yagishita N, Nishioka K, Kanazawa T, et al. The Japanese version of the 2010 American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and the fibromyalgia symptom scale: reliability and validity. Mod Rheumatol. 2012;22(1): 40-4.
6. Hoffman DL, Dukes EM. The health status burden of people with fibromyalgia: a review of studies that assessed health status with the SF-36 or the SF-12. Int J Clin Pract. 2008;62(1): 115-26.
7. Schaefer C, Chandran A, Hufstader M, Baik R, McNett M, Goldenberg D, et al. The comparative burden of mild, moderate and severe fibromyalgia: results from a cross-sectional survey in the United States. Health Qual Life Outcomes. 2011;9:71.
8. Winkelmann A, Perrot S, Schaefer C, Ryan K, Chandran A, Sadosky A, et al. Impact of fibromyalgia severity on health economic costs: results from a European cross-sectional study. Appl Health Econ Health Policy. 2011;9(2): 125-36.
9. Matsumoto M. Epidemiology of fibromyalgia [in Japanese]. Pharma Medica. 2006;24(6): 35-9.
10. Nishioka K. Research platform for fibromyalgia in Japan. Arthr Res Ther. 2012;14(suppl 1):O5.
11. Mease PJ, Clauw DJ, Arnold LM, Goldenberg DL, Witter J, Williams DA, et al. Fibromyalgia syndrome. J Rheumatol. 2005; 32(11): 2270-7.
12. Bennett RM. Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensory processing in fibromyalgia. Mayo Clin Proc. 1999;74(4): 385-98.
13. Field MJ, Cox PJ, Stott E, Melrose H, Offord J, Su TZ, et al. Identification of the a2-d-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci USA. 2006;103(46): 17537-42.
14. Arnold LM, Russell IJ, Diri EW, Duan WR, Young JP Jr, Sharma U, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008;9(9): 792-805.
15. Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, et al. Pregabalin 1008-105 Study Group. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthr Rheum. 2005;52(4): 1264-73.
16. Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP Jr, Martin SA, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008;35(3): 502-14.
17. Pauer L, Winkelmann A, Arsenault P, Jespersen A, Whelan L, Atkinson G, A0081100 Investigators, et al. An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia. J Rheumatol. 2011;38(12): 2643-52.
18. Ohta H, Oka H, Usui C, Ohkura M, Suzuki M, Nishioka K. A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia. Arthr Res Ther. 2012;14(5): R217.
19. Hays RD, Stewart AL. Sleep measures. In: Stewart AL, Ware Jr JE, editors. Measuring functioning and well-being. Durham: Duke University Press; 1992. p. 235-9.
20. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol. 1991; 18(5): 728-33.
21. Osada K, Oka H, Isomura T, Nakamura I, Tominaga K, Takahashi S, et al. Development of the Japanese version of the Fibromyalgia Impact Questionnaire (JFIQ): psychometric assessments of reliability and validity. Int J Rheum Dis. 2011;14(1): 74-80.
22. Crofford LJ, Mease PJ, Simpson SL, Young JP Jr, Martin SA, Haig GM, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, doubleblind, placebo-controlled trial with pregabalin. Pain. 2008; 136(3): 419-31.
23. Satoh J, Yagihashi S, Baba M, Suzuki M, Arakawa A, Yoshiyama T. Efficacy and safety evaluation of pregabalin treatment over 52 weeks in patients with diabetic neuropathic pain extended after a double-blind placebo-controlled trial. J Diabetes Investig. 2011;2(6): 457-63.
24. Satoh J, Yagihashi S, Baba M, Suzuki M, Arakawa A, Yoshiyama T, et al. Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial. Diabet Med. 2011;28(1): 109-16.
25. Ogawa S, Suzuki M, Arakawa A, Yoshiyama T. Long-term efficacy and safety of pregabalin in patients with postherpetic neuralgia: results of a 52-week, open-label, flexible-dose study [in Japanese]. Masui. 2010;59(8): 961-70.
26. Ogawa S, Satoh J, Arakawa A, Yoshiyama T, Suzuki M. Pregabalin treatment for peripheral neuropathic pain-a review of safety data from randomized controlled trials conducted in Japan and in the West. Drug Saf. 2012;35(10): 793-806.